View Author
patient treatment study group blood therapy response ebv load transplantation survival number cell transplantation chemotherapy analysis autologou myeloma disease month donor high-dose result thalidomide figure randomized lymphoma trial cycle remission individual t cells melphalan myeloablative ebv-specific rituximab center aids-nhl infection table prognostic relapse factor virus tetramer protocol signi effect maintenance allo-sct course cell rescue hovon marrow regimen lymphoblastic leukemia point induction randomization t-cell high-dose therapy r-dhap arm upfront treatment tetramer t cells mantle cell lymphoma outcome crohn leukemia adult progression assay aids-nhl patients volume percentage stage hospital follow-up epstein-barr signi ficantly response rate myeloablative therapy autologous sct
9 Most Recent Publications
|
Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease
(Article)
Hommes, D.W. Duijvestein, M. Zelinkova, Z. Stokkers, P.C.F. Ley, M.H.D. Stoker, J. Voermans, C. Oers, M.H.J. van Kersten, M.J. |
2011-12-01
|
|
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
(Article)
Lokhorst, H.M. Holt, B. van der Wittebol, S. Delforge, M. Berenschot, H. Bos, G.M. Jie, K.S-G. Sinnige, H. Marwijk Kooy, M. van Joosten, P. Minnema, M.C. Ammerlaan, R. van Zweegman, S. Sonneveld, P. Vellenga, E. Croockewit, S. Oers, M.H.J. van von dem Borne, P.A. Wijermans, P.W. Schaafsma, R. de Weerdt, O. |
2010-02-11
|
|
Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: A prospective sibling donor versus no-donor comparison
(Article)
Cornelissen, J.J. Holt, B. van der Wijermans, P.W. Biesma, D.H. Wittebol, S. Voogt, P.J. Baars, J.W. Zachée, P. Verdonck, L.F. Löwenberg, B. Dekker, A.W. Verhoef, G.E.G. Veer, M.B. van 't Oers, M.H.J. van Ossenkoppele, G.J. Sonneveld, P. Maertens, J. Marwijk Kooy, M. van Schaafsma, M.R. |
2009-02-05
|
|
High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients
(Article)
Veer, M.B. van 't Jong, D. de MacKenzie, M. Kluin-Nelemans, H.C. Oers, M.H.J. van Zijlstra, J. Hagenbeek, A. Putten, W.L.J. van |
2009-02-01
|
|
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: A prospective randomized HOVON trial
(Article)
Vellenga, E. Putten, W.L.J. van Huijgens, P.C. Veer, M.B. van 't Zijlstra, J.M. Fibbe, W.E. Oers, M.H.J. van Verdonck, L.F. Wijermans, P.W. Imhoff, G. van Lugtenburg, P.J. |
2008-01-15
|
|
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: Long-term follow-up of the Dutch Cooperative Group HOVON 24 trial
(Article)
Sonneveld, P. Holt, B. van der Westveer, P.H.M. Lokhorst, H.M. Segeren, C.M. Vellenga, E. Croockewit, A.J. Verhoef, G.E.G. Cornelissen, J.J. Schaafsma, M.R. Oers, M.H.J. van Wijermans, P.W. |
2007-07-01
|
|
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study
(Article)
Segeren, C.M. Wijermans, P.W. Biesma, D.H. Croockewit, A.J. Verhoef, G.E.G. Cornelissen, J.J. Marwijk Kooy, M. van Slater, R. Schaafsma, M.R. Buijt, I. Oers, M.H.J. van Wittebol, S. Baars, J.W. Fibbe, W.E. Sonneveld, P. Holt, B. van der Steijaert, M.M. Vellenga, E. Lokhorst, H.M. |
2003-01-01
|
|
Absolute level of Epstein-Barr Virus (EBV) DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma.
(Article)
Baarle, D. van Wolthers, K.C. Hovenkamp, E. Osterhaus, A.D.M.E. Miedema, F. Oers, M.H.J. van Niesters, H.G.M. |
2002-08-01
|
|
Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma
(Article)
Baarle, D. van Miedema, F. Oers, M.H.J. van Hovenkamp, E. Callan, M.F.C. Wolthers, K.C. Kostense, S. Tan, L.C. Niesters, H.G.M. Osterhaus, A.D.M.E. McMichael, A.J. |
2001-01-01
|
